Popular filter options for oligodendroglioma trials
AO Clinical Trials
View 28 AO medical studies.
PD-1 Inhibitor
ATRA + PD-1 Inhibitor for Brain Tumor
This trial is testing a new combination of drugs to treat recurrent IDH-mutant glioma. The Sponsor-Investigator believes the proposed regimen will be safe and stimulate a robust anti-tumor immune response.
Device
Intraoperative Microdialysis for Brain Tumor
This trial is looking at a new way to collect information from people with brain tumors during surgery, in order to learn more about the safety and feasibility of the new method, as well as to gather data about potential biomarkers for brain tumors.
Glioblastoma Clinical Trials
View 22 Glioblastoma medical studies.
Device
Intraoperative Microdialysis for Brain Tumor
This trial is looking at a new way to collect information from people with brain tumors during surgery, in order to learn more about the safety and feasibility of the new method, as well as to gather data about potential biomarkers for brain tumors.
Procedure
MRI-Guided Laser Ablation + Chemotherapy for Brain Cancer
This trial will use MRI and blood tests to develop a way to measure and identify when the blood brain barrier is most disrupted after treatment for brain tumors, in order to improve treatment.
Metastatic Oligodendroglioma Clinical Trials
View 30 metastatic oligodendroglioma medical studies.
PD-1 Inhibitor
ATRA + PD-1 Inhibitor for Brain Tumor
This trial is testing a new combination of drugs to treat recurrent IDH-mutant glioma. The Sponsor-Investigator believes the proposed regimen will be safe and stimulate a robust anti-tumor immune response.
Device
Intraoperative Microdialysis for Brain Tumor
This trial is looking at a new way to collect information from people with brain tumors during surgery, in order to learn more about the safety and feasibility of the new method, as well as to gather data about potential biomarkers for brain tumors.
Topoisomerase I inhibitor
Stem Cell Therapy + Chemotherapy for Brain Tumor
This trial is testing the side effects and best dose of carboxylesterase-expressing allogeneic neural stem cells given with irinotecan hydrochloride for high-grade gliomas. The hope is that the genetically modified neural stem cells will make the tumor more sensitive to the irinotecan hydrochloride, which may stop the growth of the tumor cells.
Cancer Vaccine
Dendritic Cell Vaccine for Brain Cancer
This trial is testing which combination of immunotherapy vaccines is most effective in patients with malignant glioma, a type of brain cancer. Dendritic cells, which present cell identifiers to the immune system, are isolated from the subject's blood and pulsed with tumor lysate, a combination that is hoped will stimulate the immune system to recognize and destroy the patient's brain tumor. The pulsed dendritic cells are then injected back into the patient, with or without adjuvant imiquimod or poly ICLC.
Cancer Vaccine
SurVaxM Vaccine for Brain Cancer
This trial is testing a vaccine (SurVaxM) that helps the body's immune system destroy cells that express a protein called survivin (found in up to 95% of glioblastomas and other types of cancer). The vaccine is given with Montanide ISA 51 (to create a stronger immune response) and sargramostim (to stimulate the immune system). Priming Phase: 1 dose every 2 weeks for 6 weeks. Maintenance Phase: 1 dose every 8 weeks for up to 2 years.
IDH Positive Clinical Trials
View 6 IDH positive medical studies.
PD-1 Inhibitor
ATRA + PD-1 Inhibitor for Brain Tumor
This trial is testing a new combination of drugs to treat recurrent IDH-mutant glioma. The Sponsor-Investigator believes the proposed regimen will be safe and stimulate a robust anti-tumor immune response.
Cancer Vaccine
TTRNA-DC vaccines with GM-CSF +1 More for Oligodendroglioma
This trial will include 6 patients to assess the safety and feasibility of a new cellular therapy for patients with a specific type of brain tumor that has returned or is getting worse.
Tyrosine Kinase Inhibitor
Pemigatinib for Brain Tumor
This trial is testing a drug called pemigatinib for people with recurrent glioblastoma or other primary brain tumors. Pemigatinib will be given daily on a 2-week on, 1-week off schedule. The trial will enroll about 82 people in each of 3 cohorts.
Oligodendroglioma Clinical Trials With No Placebo
View 30 oligodendroglioma medical studies that do not have a placebo group.
PD-1 Inhibitor
ATRA + PD-1 Inhibitor for Brain Tumor
This trial is testing a new combination of drugs to treat recurrent IDH-mutant glioma. The Sponsor-Investigator believes the proposed regimen will be safe and stimulate a robust anti-tumor immune response.
Device
Intraoperative Microdialysis for Brain Tumor
This trial is looking at a new way to collect information from people with brain tumors during surgery, in order to learn more about the safety and feasibility of the new method, as well as to gather data about potential biomarkers for brain tumors.
View More Oligodendroglioma Trials
See another 8 medical studies focused on oligodendroglioma.
Frequently Asked Questions
Introduction to oligodendroglioma
What are the top hospitals conducting oligodendroglioma research?
Advancements in the understanding and treatment of oligodendroglioma, a rare type of brain tumor, are being made by top hospitals across the United States. One such institution making significant strides is Memorial Sloan Kettering Cancer Center in New york City. With six active clinical trials dedicated to this condition and a total of 11 conducted throughout their history, they have been at the forefront since recording their first trial in 2002. In Winston-Salem, North carolina, Wake Forest University Health Sciences is also actively involved in oligodendroglioma research with three ongoing trials and a notable nine completed studies since initiating their first trial in 2004.
Not too far away at Washington University School of Medicine in Saint Louis, Missouri, researchers are working diligently on three active oligodendroglioma trials alongside eight previous investigations which date back to their pioneering efforts starting from 2004. Meanwhile, M D Anderson Cancer Center located in Houston takes pride not only having achieved conducting present-day trio but has also marked its imprint with accomplishing just asmany past experiments dealing with this particular type of brain tumor; it all began for them back then around two decades ago.
Dana Farber Cancer Institute adds itself to this prestigious list as well with three ongoing clinical trials focused on oligodendroglioma along withinvolvement within five similar endeavors dated from year2005 onwards exclusively based out Boston's medical landscape.This collective effort among these renowned hospitals demonstrates commitment towards advancing knowledge about oligodendroglioma and improving outcomes for patients affected by this rare neurological disease that impacts individuals worldwide.
Which are the best cities for oligodendroglioma clinical trials?
The top cities for oligodendroglioma clinical trials are Boston, Houston, and New york. These cities have 9 active trials each that focus on various treatments such as rQNestin, dabrafenib, Proton Beam Radiation Therapy, INCB7839, and Pemigatinib. With a strong presence in research and development, these cities offer individuals with oligodendroglioma access to cutting-edge clinical trials that explore innovative treatment options and potentially contribute to advancements in care.
Which are the top treatments for oligodendroglioma being explored in clinical trials?
Oligodendroglioma, a rare form of brain tumor, is currently being targeted in clinical trials with several promising treatments. A pharmacological study takes the lead with two active trials and 11 all-time oligodendroglioma trials since its introduction in 2003. Another avenue of exploration involves combining cetuximab and bevacizumab through SIACI, showing potential in one ongoing trial that marks its debut on the scene in 2023. Additionally, craniotomy—a surgical procedure—holds promise as another treatment option under investigation with one active trial listed for oligodendroglioma. Finally, retifanlimab shows encouraging results as it enters the field with one ongoing trial following its first listing just last year (2022). As researchers delve deeper into these avenues for treating oligodendroglioma, there is hope for improved outcomes and an increased quality of life for patients facing this challenging diagnosis.
What are the most recent clinical trials for oligodendroglioma?
A multitude of recent clinical trials have emerged, bringing hope and potential advancements for individuals with oligodendroglioma. These trials include a phase 1 study exploring the effectiveness of low-dose OKN-007 administered twice daily, a single-arm trial investigating new treatment options specific to oligodendroglioma, and Phase 1 studies evaluating neural stem cells expressing CRAd-S-pk7 as well as surVaxM in patients who experienced relapse or progression. These groundbreaking endeavors provide promising prospects for improved outcomes in the management of oligodendroglioma.
What oligodendroglioma clinical trials were recently completed?
Recent advancements in oligodendroglioma clinical trials have brought hope for improved treatments. In January 2019, the National Cancer Institute wrapped up a trial investigating LB-100, demonstrating progress in understanding its potential against this complex brain tumor. Additionally, Northwestern University completed a trial in April 2017 examining neural stem cells loaded with an oncolytic adenovirus as a possible therapeutic approach. These milestones highlight ongoing efforts to address the challenges of oligodendroglioma and offer promising avenues for future research and treatment options.